Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2012 Feb 15;307(7):674-84.
doi: 10.1001/jama.2012.120.
Evan Appelbaum, Yili Pritchett, Yuchiao Chang, Julia Wenger, Hector Tamez, Ishir Bhan, Rajiv Agarwal, Carmine Zoccali, Christoph Wanner, Donald Lloyd-Jones, Jorge Cannata, B Taylor Thompson, Dennis Andress, Wuyan Zhang, David Packham, Bhupinder Singh, Daniel Zehnder, Amil Shah, Ajay Pachika, Warren J Manning, Scott D Solomon
Affiliations
- PMID: 22337679
- DOI: 10.1001/jama.2012.120
Randomized Controlled Trial
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial
Ravi Thadhani et al. JAMA. 2012.
Abstract
Context: Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure and function, yet firm evidence for either remains lacking.
Objective: To determine the effects of an active vitamin D compound, paricalcitol, on left ventricular mass over 48 weeks in patients with an estimated glomerular filtration rate of 15 to 60 mL/min/1.73 m(2).
Design, setting, and participants: Multinational, double-blind, randomized placebo-controlled trial among 227 patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, conducted in 11 countries from July 2008 through September 2010.
Intervention: Participants were randomly assigned to receive oral paricalcitol, 2 μg/d (n =115), or matching placebo (n = 112).
Main outcome measures: Change in left ventricular mass index over 48 weeks by cardiovascular magnetic resonance imaging. Secondary end points included echocardiographic changes in left ventricular diastolic function.
Results: Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. At 48 weeks, the change in left ventricular mass index did not differ between treatment groups (paricalcitol group, 0.34 g/m(2.7) [95% CI, -0.14 to 0.83 g/m(2.7)] vs placebo group, -0.07 g/m(2.7) [95% CI, -0.55 to 0.42 g/m(2.7)]). Doppler measures of diastolic function including peak early diastolic lateral mitral annular tissue velocity (paricalcitol group, -0.01 cm/s [95% CI, -0.63 to 0.60 cm/s] vs placebo group, -0.30 cm/s [95% CI, -0.93 to 0.34 cm/s]) also did not differ. Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group.
Conclusion: Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease.
Trial registration: clinicaltrials.gov Identifier: NCT00497146.
Comment in
- Vitamin D in chronic kidney disease: more questions than answers.
Anker SD, von Haehling S. Anker SD, et al. JAMA. 2012 Feb 15;307(7):722-3. doi: 10.1001/jama.2012.159. JAMA. 2012. PMID: 22337683 No abstract available. - Vitamin D therapy and cardiac function in chronic kidney disease.
Fourtounas C. Fourtounas C. JAMA. 2012 Jun 6;307(21):2253; author reply 2254. doi: 10.1001/jama.2012.4168. JAMA. 2012. PMID: 22706819 No abstract available. - Vitamin D therapy and cardiac function in chronic kidney disease.
Rajagopalan S, Chan CT. Rajagopalan S, et al. JAMA. 2012 Jun 6;307(21):2253; author reply 2254. doi: 10.1001/jama.2012.4170. JAMA. 2012. PMID: 22706820 No abstract available. - Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy.
Fedele F, Frati G, Biondi-Zoccai G. Fedele F, et al. Int J Cardiol. 2013 Sep 1;167(5):2343-4. doi: 10.1016/j.ijcard.2012.11.040. Epub 2012 Nov 22. Int J Cardiol. 2013. PMID: 23176772 No abstract available.
Similar articles
- Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Wang AY, et al. J Am Soc Nephrol. 2014 Jan;25(1):175-86. doi: 10.1681/ASN.2013010103. Epub 2013 Sep 19. J Am Soc Nephrol. 2014. PMID: 24052631 Free PMC article. Clinical Trial. - Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.
Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Tamez H, et al. Am Heart J. 2012 Dec;164(6):902-9.e2. doi: 10.1016/j.ahj.2012.09.018. Epub 2012 Oct 29. Am Heart J. 2012. PMID: 23194491 Clinical Trial. - Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy.
Fedele F, Frati G, Biondi-Zoccai G. Fedele F, et al. Int J Cardiol. 2013 Sep 1;167(5):2343-4. doi: 10.1016/j.ijcard.2012.11.040. Epub 2012 Nov 22. Int J Cardiol. 2013. PMID: 23176772 No abstract available. - Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Cheng J, Zhang W, Zhang X, Li X, Chen J. Cheng J, et al. Clin J Am Soc Nephrol. 2012 Mar;7(3):391-400. doi: 10.2215/CJN.03000311. Epub 2012 Jan 5. Clin J Am Soc Nephrol. 2012. PMID: 22223607 Review. - Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.
Cheng S, Coyne D. Cheng S, et al. Expert Opin Pharmacother. 2006 Apr;7(5):617-21. doi: 10.1517/14656566.7.5.617. Expert Opin Pharmacother. 2006. PMID: 16553577 Review.
Cited by
- Native vitamin D in CKD and renal transplantation: meaning and rationale for its supplementation.
Alfieri C, Molinari P, Vettoretti S, Fusaro M, Bover J, Cianciolo G, Pisacreta AM, Di Naro M, Castellano G. Alfieri C, et al. J Nephrol. 2024 Sep 2. doi: 10.1007/s40620-024-02055-x. Online ahead of print. J Nephrol. 2024. PMID: 39223353 Review. - Impact of successful secondary hyperparathyroidism treatment on cardiovascular morbidity in patients with chronic kidney disease KDIGO stages G3b-5.
Da Canal F, Breuer E, Hübel K, Mikulicic F, Buechel RR, de Rougemont O, Seeger H, Vetter D. Da Canal F, et al. Ir J Med Sci. 2024 Aug 31. doi: 10.1007/s11845-024-03770-x. Online ahead of print. Ir J Med Sci. 2024. PMID: 39215777 - Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence.
Yeung WG, Toussaint ND, Badve SV. Yeung WG, et al. Clin Kidney J. 2024 Jul 18;17(8):sfae227. doi: 10.1093/ckj/sfae227. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39119524 Free PMC article. Review. - Vitamin D and cardiovascular diseases: A narrative review.
Alissa EM. Alissa EM. J Family Med Prim Care. 2024 Apr;13(4):1191-1199. doi: 10.4103/jfmpc.jfmpc_1481_23. Epub 2024 Apr 22. J Family Med Prim Care. 2024. PMID: 38827691 Free PMC article. Review. - Association of 1,25 dihydroxyvitamin D with left ventricular hypertrophy and left ventricular diastolic dysfunction in patients with chronic kidney disease.
Hyeon J, Kim S, Ye BM, Kim SR, Lee DW, Lee SB, Kim IY. Hyeon J, et al. PLoS One. 2024 May 9;19(5):e0302849. doi: 10.1371/journal.pone.0302849. eCollection 2024. PLoS One. 2024. PMID: 38722953 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical